<DOC>
	<DOCNO>NCT00115635</DOCNO>
	<brief_summary>The aim study determine optimal dose combination docetaxel gemcitabine patient hormone refractory prostate cancer , evaluate dose respect efficacy toxicity phase II trial .</brief_summary>
	<brief_title>Docetaxel Gemcitabine Hormonal Refractory Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically verify adenocarcinoma prostate . Hormone refractory prostate cancer ( HRPC ) define progression previous antihormone treatment . Patients must previous antiandrogen therapy 4 week . Stage IV disease ( verified image clinical examination ) . PSA &gt; 10 microgram/l . PSA progression define &gt; 25 % increase two independent measurement perform 1month interval discontinuation antiandrogen treatment . Castrate level testosterone ( &lt; 50 ng ) . No previous oestrogen steroid metastatic prostate cancer treatment . Satisfactory hepatic function form total bilirubin ≤ UNL ( upper normal limit ) , ASAT/ALAT ≤ 2.5 x UNL , alkaline phosphatase ≤ 5 x UNL . Satisfactory renal function , define serum creatinine ≤ 1.5 x UNL . Satisfactory haematologic function define ANC &gt; 1.5 x 10^9/l , leucocytes &gt; 3.0 x 10^9/l , thrombocytes ≥ 100 x 10^9/l , haemoglobin &gt; 7 mmol/l ECOG performance status ≤ 2 . Life expectancy &gt; 3 month . Patient must able adhere protocol requirement . Written informed consent . &gt; 18 year age . Previous prostate cancer treatment oestrogens steroid hormone . Previous chemotherapy . Previous treatment systemic radioactive isotope . Bisphosphonate treatment ( concomitant ) . Radiation therapy cover 25 % bone marrow produce area . Other serious coincidental and/or concomitant medical condition . Symptomatic cerebral metastasis . Other previous current malignant disease , exclude *adequately treat cure planocellular skin carcinoma ; *other cancer assess carry minimal risk recurrence . ECOG performance status &gt; 2 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Hormonal refractory , chemotherapy , docetaxel , gemcitabine</keyword>
</DOC>